Ethical Approaches to Managing Expectations in Rare Disease Trials

Why Managing Expectations Is Crucial in Rare Disease Research

High-profile rare disease trials often attract intense interest from patients, caregivers, and the broader community. These studies typically address life-threatening conditions for which no treatment exists, creating an emotionally charged environment where hope can quickly blur with unrealistic expectations.

Without proactive strategies to manage expectations, sponsors and investigators risk patient disappointment, decreased trust, and even early withdrawal from the study. Worse, patients may conflate research participation with guaranteed access to effective treatment—a phenomenon known as therapeutic misconception.

Ethically managing expectations is therefore not just a communication issue—it is integral to informed consent, participant protection, and overall trial integrity.

Sources of Misaligned Expectations in Rare Disease Trials

Misunderstandings and inflated hopes in rare disease trials can arise from a number of sources:

• Media hype: Breakthrough therapy designations or press releases often frame studies as curative, even when evidence is preliminary.
• Unmet need: Patients and families desperate for a solution may focus solely on potential benefits, overlooking the possibility of no effect or placebo assignment.
• Lack of scientific understanding: Complex trial designs, such as adaptive protocols or dose-ranging studies, may be difficult to explain in lay terms.
• Limited previous trial experience: Many rare disease patients are first-time participants, unfamiliar with standard clinical trial risks and uncertainties.

For example, in a gene therapy trial for spinal muscular atrophy (SMA), several families withdrew mid-study after learning that not all participants would receive the investigational drug immediately—highlighting the need for clearer expectation setting during recruitment.

Key Ethical Principles in Expectation Management

Expectation management should be grounded in ethical frameworks that protect patient autonomy while maintaining hope. Key principles include:

• Transparency: Clearly explain the study’s purpose, design, risks, and limitations without ambiguity.
• Realism: Emphasize that participation is for research—not treatment—and outcomes are uncertain.
• Compassion: Communicate with empathy, especially when delivering difficult information (e.g., placebo allocation).
• Empowerment: Encourage questions and ensure patients feel they have agency in their decision to participate.

These align with international research ethics guidelines such as the Declaration of Helsinki and FDA’s guidance on informed consent.

Practical Strategies for Sponsors and Investigators

To ethically manage expectations throughout the trial lifecycle, stakeholders should consider the following:

During Trial Planning

• Include patient advisory boards to identify common misconceptions and emotional triggers.
• Prepare lay-friendly summaries of the protocol, including flowcharts and FAQs.
• Train all site staff in expectation management and sensitive communication.

During Informed Consent

• Use plain language and avoid overly optimistic phrasing (e.g., “breakthrough therapy”).
• Clearly define what participation does and does not include (e.g., access to drug post-trial).
• Ask comprehension questions to ensure true understanding—not just signature compliance.

During Study Participation

• Provide ongoing, consistent communication about trial status, timelines, and expectations.
• Use newsletters or portals to share general updates without individualizing data.
• Offer emotional and logistical support through social workers or nurse coordinators.

After Study Completion

• Debrief participants about study outcomes and next steps, regardless of results.
• Avoid making commitments about regulatory approval or access unless officially confirmed.
• Continue to engage patients via advocacy channels or registries to maintain trust.

Case Study: Managing Expectations in a Duchenne Trial

In a phase II trial for Duchenne Muscular Dystrophy, several families entered the study believing their children would receive curative treatment. When the placebo arm was explained post-randomization, some withdrew, while others expressed anger toward site staff. In response, the sponsor revised its consent materials to include visual diagrams, introduced pre-screening counseling sessions, and brought in an advocacy liaison to support families.

Retention rates improved by 22% in the subsequent cohort, and patient satisfaction scores in end-of-study surveys increased significantly—demonstrating the power of effective expectation management.

The Role of Advocacy Groups and Peer Counselors

Patient advocacy groups can serve as vital allies in communicating realistic trial expectations. Their existing trust networks allow them to:

• Provide neutral, experience-based insights into the trial process
• Host webinars or Q&A sessions for prospective participants
• Disseminate accurate trial information in digestible formats
• Support peer mentoring between experienced and first-time trial participants

Some sponsors have even included trained peer counselors in their site teams to support emotionally vulnerable families through complex decisions.

Measuring and Monitoring Expectations Over Time

To identify and mitigate mismatched expectations during the trial, sponsors should implement periodic assessments. Methods include:

• Patient surveys focused on satisfaction, understanding, and emotional state
• Exit interviews for withdrawals to assess whether disappointment contributed
• Communication audits of site calls and newsletters

Such data can inform continuous improvement and serve as supporting documentation in regulatory or ethics reviews.

Conclusion: Balancing Hope with Honesty

Rare disease patients and their families enter clinical trials with understandable hope—but it is the duty of sponsors and investigators to ensure that hope is grounded in reality. Through clear communication, cultural sensitivity, ethical consent practices, and patient partnership, it is possible to maintain both scientific rigor and human compassion.

Managing expectations isn’t just about avoiding disappointment—it’s about fostering long-term trust, retention, and advocacy within the rare disease community. In doing so, we pave the way for ethically sound and operationally successful research programs that truly serve the needs of patients.